Jun. 25 at 9:21 PM
eXoZymes (Nasdaq:
$EXOZ) secures
$2 million NIH grant, expanding its proprietary pharmaceutical biosolutions pipeline into non-intoxicating cannabinoids.
Federal research funding extends eXoZymes’ cell-free platform further into drug discovery. eXoZymes Inc. (Nasdaq: EXOZ) has received a Notice of Award from the National Institutes of Health for a roughly
$2 million Phase IIB SBIR grant to produce rare cannabinoids and engineer cannabinoid analogs for pharmaceutical evaluation. The award adds a second biosolution to the pipeline alongside NCT, expands the company’s portfolio of proprietary pharmaceutical assets, and lifts total non-dilutive funding awarded to eXoZymes and its predecessor programs to approximately
$19.7 million. The two-year program begins July 1, 2026.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1
Michael Heltzen, CEO of eXoZymes, commented: “This is a key milestone that demonstrates our repeatable development engine of future licensing and partnering opportunities - a key feature in creating additional proprietary molecules without diluting shareholders.”
From the announcement:
• The grant supports work to build cannabinoid cyclase expression systems, widen the analog range, and run preclinical receptor-binding evaluation of the cannabinoid library
• It arrives as the US minor cannabinoids market is forecast to grow from
$11.5 billion in 2023 to
$33.3 billion by 2030
See the full release: https://exozymes.com/blog/grant-cannabinoid-analogs
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
$DNLI,
$TWST,
$DNA,
$ARKG